| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Atrial Fibrillation | 39 | 2023 | 186 | 6.110 |
Why?
|
| Pacemaker, Artificial | 33 | 2022 | 50 | 5.870 |
Why?
|
| Catheter Ablation | 27 | 2022 | 81 | 5.750 |
Why?
|
| Cardiac Pacing, Artificial | 41 | 2022 | 84 | 5.250 |
Why?
|
| Defibrillators, Implantable | 19 | 2023 | 33 | 4.900 |
Why?
|
| Arrhythmias, Cardiac | 31 | 2023 | 153 | 4.240 |
Why?
|
| Electrocardiography | 48 | 2022 | 219 | 3.930 |
Why?
|
| Tachycardia, Ventricular | 16 | 2023 | 35 | 3.370 |
Why?
|
| Cardiac Resynchronization Therapy | 10 | 2023 | 21 | 3.070 |
Why?
|
| Pulmonary Veins | 5 | 2020 | 24 | 3.010 |
Why?
|
| Heart Failure | 14 | 2022 | 207 | 3.010 |
Why?
|
| Bundle of His | 14 | 2022 | 32 | 2.550 |
Why?
|
| Anti-Arrhythmia Agents | 18 | 2022 | 110 | 2.470 |
Why?
|
| Humans | 160 | 2023 | 29851 | 1.910 |
Why?
|
| Electric Countershock | 14 | 2017 | 32 | 1.830 |
Why?
|
| Atrial Flutter | 14 | 2011 | 21 | 1.730 |
Why?
|
| Amiodarone | 8 | 2018 | 29 | 1.640 |
Why?
|
| Cryosurgery | 3 | 2020 | 20 | 1.620 |
Why?
|
| Heart Rate | 13 | 2020 | 152 | 1.430 |
Why?
|
| Body Surface Potential Mapping | 3 | 2019 | 7 | 1.370 |
Why?
|
| Tachycardia, Supraventricular | 8 | 2017 | 11 | 1.330 |
Why?
|
| Middle Aged | 78 | 2022 | 9963 | 1.300 |
Why?
|
| Bundle-Branch Block | 10 | 2023 | 16 | 1.270 |
Why?
|
| Ventricular Fibrillation | 14 | 2023 | 32 | 1.230 |
Why?
|
| Electrodes, Implanted | 12 | 2015 | 47 | 1.190 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 4 | 2020 | 8 | 1.170 |
Why?
|
| Anticoagulants | 10 | 2021 | 102 | 1.150 |
Why?
|
| Heart Ventricles | 17 | 2022 | 169 | 1.110 |
Why?
|
| Female | 75 | 2022 | 16430 | 1.080 |
Why?
|
| Male | 89 | 2022 | 15871 | 1.080 |
Why?
|
| Action Potentials | 5 | 2020 | 139 | 1.070 |
Why?
|
| Heart Diseases | 3 | 2023 | 75 | 1.060 |
Why?
|
| Heart Block | 11 | 2017 | 19 | 1.030 |
Why?
|
| Vena Cava, Superior | 3 | 2015 | 4 | 0.970 |
Why?
|
| Device Removal | 2 | 2015 | 86 | 0.950 |
Why?
|
| Radiography, Interventional | 3 | 2020 | 25 | 0.900 |
Why?
|
| Heart Arrest | 8 | 2011 | 59 | 0.890 |
Why?
|
| Risk Assessment | 6 | 2020 | 685 | 0.870 |
Why?
|
| Treatment Outcome | 27 | 2022 | 3561 | 0.850 |
Why?
|
| Prosthesis Implantation | 2 | 2016 | 35 | 0.840 |
Why?
|
| Prosthesis Failure | 2 | 2018 | 530 | 0.800 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2021 | 3 | 0.780 |
Why?
|
| Heart Conduction System | 14 | 2023 | 34 | 0.780 |
Why?
|
| Chest Pain | 1 | 2021 | 24 | 0.770 |
Why?
|
| Aged | 54 | 2022 | 9621 | 0.760 |
Why?
|
| Ventricular Dysfunction, Left | 3 | 2020 | 42 | 0.760 |
Why?
|
| Cardiac Catheterization | 4 | 2018 | 93 | 0.760 |
Why?
|
| Radiation Exposure | 2 | 2020 | 8 | 0.750 |
Why?
|
| Radiation Dosage | 2 | 2020 | 32 | 0.750 |
Why?
|
| Tachycardia | 12 | 2009 | 53 | 0.740 |
Why?
|
| Atrial Appendage | 2 | 2020 | 45 | 0.730 |
Why?
|
| Septal Occluder Device | 1 | 2020 | 17 | 0.730 |
Why?
|
| Time Factors | 18 | 2021 | 1641 | 0.700 |
Why?
|
| Torsades de Pointes | 3 | 2007 | 11 | 0.680 |
Why?
|
| Dextrocardia | 1 | 2018 | 3 | 0.650 |
Why?
|
| Thyroid Diseases | 1 | 2018 | 13 | 0.640 |
Why?
|
| Risk Factors | 15 | 2020 | 2467 | 0.630 |
Why?
|
| Thyroid Gland | 1 | 2018 | 26 | 0.630 |
Why?
|
| Bradycardia | 6 | 2021 | 29 | 0.630 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2019 | 222 | 0.620 |
Why?
|
| Atrioventricular Block | 1 | 2017 | 2 | 0.610 |
Why?
|
| Accessory Atrioventricular Bundle | 1 | 2017 | 2 | 0.610 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2018 | 29 | 0.610 |
Why?
|
| Fluoroscopy | 5 | 2020 | 54 | 0.600 |
Why?
|
| Heart Atria | 6 | 2011 | 74 | 0.590 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 7 | 2019 | 11 | 0.570 |
Why?
|
| Cardiomyopathies | 2 | 2022 | 31 | 0.540 |
Why?
|
| Recurrence | 11 | 2022 | 355 | 0.540 |
Why?
|
| Therapeutic Occlusion | 1 | 2015 | 2 | 0.530 |
Why?
|
| Intraoperative Care | 1 | 2016 | 44 | 0.530 |
Why?
|
| Thrombosis | 3 | 2014 | 59 | 0.530 |
Why?
|
| Vena Cava, Inferior | 1 | 2015 | 11 | 0.530 |
Why?
|
| Equipment Design | 14 | 2022 | 186 | 0.530 |
Why?
|
| Echocardiography, Transesophageal | 5 | 2014 | 46 | 0.510 |
Why?
|
| Takotsubo Cardiomyopathy | 2 | 2015 | 12 | 0.510 |
Why?
|
| Long QT Syndrome | 3 | 2020 | 17 | 0.480 |
Why?
|
| Adenosine | 3 | 2009 | 12 | 0.480 |
Why?
|
| Heart Defects, Congenital | 2 | 2008 | 30 | 0.470 |
Why?
|
| Equipment Failure | 9 | 2008 | 53 | 0.470 |
Why?
|
| Feasibility Studies | 5 | 2021 | 230 | 0.460 |
Why?
|
| Shock, Cardiogenic | 2 | 2012 | 10 | 0.450 |
Why?
|
| Stroke | 4 | 2012 | 294 | 0.440 |
Why?
|
| Warfarin | 6 | 2018 | 38 | 0.440 |
Why?
|
| Coronary Vasospasm | 2 | 2012 | 2 | 0.430 |
Why?
|
| Hypothermia, Induced | 1 | 2012 | 22 | 0.420 |
Why?
|
| Models, Animal | 1 | 2012 | 128 | 0.420 |
Why?
|
| Ventricular Function, Left | 5 | 2022 | 49 | 0.410 |
Why?
|
| Myocardial Ischemia | 1 | 2012 | 49 | 0.410 |
Why?
|
| Retrospective Studies | 15 | 2021 | 3325 | 0.400 |
Why?
|
| Heart Valves | 1 | 2011 | 5 | 0.400 |
Why?
|
| Thiophenes | 1 | 2011 | 13 | 0.390 |
Why?
|
| Prognosis | 9 | 2018 | 874 | 0.390 |
Why?
|
| Electric Injuries | 2 | 2011 | 3 | 0.380 |
Why?
|
| Granuloma, Foreign-Body | 1 | 2010 | 4 | 0.370 |
Why?
|
| Myocardial Infarction | 11 | 2020 | 175 | 0.370 |
Why?
|
| Hospitals | 1 | 2011 | 157 | 0.370 |
Why?
|
| Transposition of Great Vessels | 3 | 2008 | 6 | 0.360 |
Why?
|
| Heart | 7 | 2022 | 96 | 0.360 |
Why?
|
| Coronary Occlusion | 1 | 2010 | 2 | 0.360 |
Why?
|
| Cardiography, Impedance | 1 | 2010 | 2 | 0.360 |
Why?
|
| Defibrillators | 1 | 2010 | 3 | 0.360 |
Why?
|
| Pericardium | 3 | 2008 | 20 | 0.350 |
Why?
|
| Adult | 28 | 2021 | 8748 | 0.350 |
Why?
|
| Prospective Studies | 6 | 2020 | 1824 | 0.350 |
Why?
|
| Electromagnetic Fields | 4 | 2007 | 13 | 0.340 |
Why?
|
| Aged, 80 and over | 14 | 2022 | 4930 | 0.330 |
Why?
|
| Coronary Angiography | 7 | 2011 | 91 | 0.330 |
Why?
|
| Heart Transplantation | 2 | 1999 | 37 | 0.320 |
Why?
|
| Iliac Vein | 1 | 2008 | 5 | 0.320 |
Why?
|
| Atrioventricular Node | 4 | 2000 | 6 | 0.320 |
Why?
|
| Career Choice | 1 | 2008 | 31 | 0.310 |
Why?
|
| Pediatrics | 1 | 2008 | 33 | 0.310 |
Why?
|
| Echocardiography | 6 | 2019 | 173 | 0.300 |
Why?
|
| Prostheses and Implants | 5 | 1991 | 165 | 0.300 |
Why?
|
| Cardiology | 1 | 2008 | 73 | 0.300 |
Why?
|
| Tachycardia, Paroxysmal | 2 | 2006 | 4 | 0.300 |
Why?
|
| Animals | 7 | 2022 | 4639 | 0.290 |
Why?
|
| Physicians | 1 | 2008 | 116 | 0.280 |
Why?
|
| Electrocoagulation | 2 | 2022 | 16 | 0.280 |
Why?
|
| Critical Illness | 1 | 2008 | 127 | 0.280 |
Why?
|
| Stroke Volume | 7 | 2022 | 61 | 0.280 |
Why?
|
| Predictive Value of Tests | 6 | 2019 | 532 | 0.280 |
Why?
|
| Cardiac Surgical Procedures | 3 | 2005 | 43 | 0.270 |
Why?
|
| Reoperation | 4 | 2020 | 927 | 0.270 |
Why?
|
| Registries | 3 | 2021 | 191 | 0.270 |
Why?
|
| Heart-Assist Devices | 2 | 2013 | 22 | 0.270 |
Why?
|
| Azithromycin | 1 | 2005 | 4 | 0.270 |
Why?
|
| Cardiopulmonary Bypass | 2 | 2015 | 17 | 0.250 |
Why?
|
| Procainamide | 4 | 1999 | 24 | 0.240 |
Why?
|
| Signal Processing, Computer-Assisted | 3 | 2019 | 40 | 0.240 |
Why?
|
| Diagnosis, Differential | 4 | 2020 | 399 | 0.240 |
Why?
|
| Exercise Test | 3 | 2020 | 124 | 0.230 |
Why?
|
| Sick Sinus Syndrome | 6 | 1994 | 7 | 0.230 |
Why?
|
| Sensitivity and Specificity | 6 | 2015 | 558 | 0.220 |
Why?
|
| Follow-Up Studies | 17 | 2013 | 1859 | 0.220 |
Why?
|
| Tachycardia, Atrioventricular Nodal Reentry | 3 | 2000 | 3 | 0.200 |
Why?
|
| Thromboembolism | 3 | 2011 | 19 | 0.190 |
Why?
|
| Ventricular Function, Right | 3 | 2019 | 7 | 0.190 |
Why?
|
| Cardiovascular Diseases | 1 | 2005 | 411 | 0.190 |
Why?
|
| Vectorcardiography | 1 | 2020 | 1 | 0.190 |
Why?
|
| Methohexital | 2 | 1999 | 3 | 0.190 |
Why?
|
| Metabolic Equivalent | 1 | 2020 | 3 | 0.190 |
Why?
|
| Pre-Excitation Syndromes | 1 | 2000 | 1 | 0.190 |
Why?
|
| Sinoatrial Node | 1 | 2020 | 5 | 0.190 |
Why?
|
| Ventricular Function | 1 | 2000 | 16 | 0.190 |
Why?
|
| Atrial Function | 1 | 2000 | 14 | 0.190 |
Why?
|
| Anesthetics, Intravenous | 2 | 1999 | 13 | 0.190 |
Why?
|
| Software | 1 | 2001 | 72 | 0.190 |
Why?
|
| Prone Position | 1 | 2020 | 29 | 0.190 |
Why?
|
| Electrophysiological Phenomena | 1 | 2020 | 11 | 0.190 |
Why?
|
| Hemodynamics | 5 | 2013 | 90 | 0.190 |
Why?
|
| Exercise Tolerance | 1 | 2020 | 32 | 0.180 |
Why?
|
| Lasers | 1 | 2020 | 16 | 0.180 |
Why?
|
| Treatment Failure | 2 | 2020 | 161 | 0.180 |
Why?
|
| Algorithms | 4 | 2019 | 401 | 0.180 |
Why?
|
| Forecasting | 2 | 2017 | 117 | 0.180 |
Why?
|
| Myocardial Perfusion Imaging | 2 | 2013 | 57 | 0.180 |
Why?
|
| Endoscopy, Gastrointestinal | 2 | 2012 | 10 | 0.180 |
Why?
|
| Wolff-Parkinson-White Syndrome | 2 | 2000 | 4 | 0.170 |
Why?
|
| Antiviral Agents | 1 | 2020 | 136 | 0.170 |
Why?
|
| Antibiotics, Antitubercular | 1 | 1999 | 4 | 0.170 |
Why?
|
| Rifampin | 1 | 1999 | 7 | 0.170 |
Why?
|
| Pilot Projects | 1 | 2020 | 403 | 0.170 |
Why?
|
| Thyroid Function Tests | 1 | 2018 | 8 | 0.160 |
Why?
|
| Cardiomyopathy, Hypertrophic | 4 | 2001 | 8 | 0.160 |
Why?
|
| Diagnostic Errors | 1 | 2018 | 40 | 0.160 |
Why?
|
| Tachycardia, Ectopic Atrial | 2 | 1995 | 2 | 0.160 |
Why?
|
| Electrodes | 2 | 2015 | 16 | 0.160 |
Why?
|
| Graft Rejection | 1 | 1998 | 75 | 0.160 |
Why?
|
| Adolescent | 6 | 2009 | 2334 | 0.150 |
Why?
|
| Ablation Techniques | 1 | 2017 | 3 | 0.150 |
Why?
|
| Swine | 3 | 2022 | 84 | 0.150 |
Why?
|
| Anesthesia, Intravenous | 1 | 1997 | 8 | 0.150 |
Why?
|
| Personnel, Hospital | 1 | 1997 | 18 | 0.140 |
Why?
|
| History, 21st Century | 1 | 2017 | 37 | 0.140 |
Why?
|
| Diffusion of Innovation | 1 | 2017 | 38 | 0.140 |
Why?
|
| History, 20th Century | 1 | 2017 | 91 | 0.140 |
Why?
|
| Exercise | 1 | 2020 | 474 | 0.140 |
Why?
|
| Aortic Valve Insufficiency | 2 | 1994 | 9 | 0.130 |
Why?
|
| Constriction | 1 | 2015 | 4 | 0.130 |
Why?
|
| Infusions, Intravenous | 3 | 2009 | 78 | 0.130 |
Why?
|
| Contraindications | 1 | 2015 | 42 | 0.130 |
Why?
|
| Postoperative Complications | 6 | 1994 | 957 | 0.130 |
Why?
|
| Fatal Outcome | 2 | 2010 | 60 | 0.130 |
Why?
|
| Patient Selection | 2 | 2014 | 234 | 0.130 |
Why?
|
| Patient Care Planning | 1 | 1995 | 56 | 0.120 |
Why?
|
| Heart Neoplasms | 1 | 2014 | 14 | 0.120 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2014 | 16 | 0.120 |
Why?
|
| Incidence | 6 | 2020 | 759 | 0.120 |
Why?
|
| Coronary Vessels | 1 | 1994 | 46 | 0.120 |
Why?
|
| Myocardial Contraction | 4 | 1999 | 77 | 0.120 |
Why?
|
| Coronary Disease | 5 | 1999 | 87 | 0.120 |
Why?
|
| Electrocardiography, Ambulatory | 6 | 1998 | 21 | 0.120 |
Why?
|
| Electrophysiology | 9 | 1997 | 134 | 0.120 |
Why?
|
| Fistula | 1 | 1994 | 4 | 0.120 |
Why?
|
| Selection Bias | 1 | 1994 | 10 | 0.120 |
Why?
|
| Bioprosthesis | 1 | 1994 | 8 | 0.120 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 1126 | 0.120 |
Why?
|
| Verapamil | 3 | 2000 | 38 | 0.120 |
Why?
|
| Endocarditis, Bacterial | 1 | 1994 | 10 | 0.120 |
Why?
|
| Multivariate Analysis | 4 | 1999 | 332 | 0.120 |
Why?
|
| Streptococcal Infections | 1 | 1994 | 14 | 0.120 |
Why?
|
| Heart Valve Prosthesis | 1 | 1994 | 21 | 0.120 |
Why?
|
| Sex Factors | 2 | 2012 | 498 | 0.110 |
Why?
|
| Sarcoma | 1 | 2014 | 133 | 0.100 |
Why?
|
| Embolism | 1 | 1992 | 4 | 0.100 |
Why?
|
| Hemostasis, Endoscopic | 1 | 2012 | 1 | 0.100 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2013 | 75 | 0.100 |
Why?
|
| Cause of Death | 3 | 2013 | 64 | 0.100 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2012 | 22 | 0.100 |
Why?
|
| Cerebrovascular Disorders | 1 | 1993 | 139 | 0.100 |
Why?
|
| Intercostal Muscles | 1 | 2011 | 3 | 0.100 |
Why?
|
| Primary Health Care | 1 | 2013 | 95 | 0.100 |
Why?
|
| Spasm | 1 | 2011 | 7 | 0.100 |
Why?
|
| Coronary Sinus | 1 | 2011 | 3 | 0.100 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2012 | 79 | 0.100 |
Why?
|
| Foreign-Body Migration | 1 | 1991 | 20 | 0.100 |
Why?
|
| Therapeutic Irrigation | 2 | 2022 | 66 | 0.100 |
Why?
|
| Environmental Exposure | 2 | 2002 | 16 | 0.100 |
Why?
|
| Coronary Artery Bypass | 1 | 1991 | 31 | 0.100 |
Why?
|
| Young Adult | 1 | 2017 | 1969 | 0.100 |
Why?
|
| Duloxetine Hydrochloride | 1 | 2011 | 10 | 0.100 |
Why?
|
| Electricity | 2 | 2002 | 10 | 0.100 |
Why?
|
| Hormone Replacement Therapy | 1 | 2011 | 30 | 0.090 |
Why?
|
| Security Measures | 2 | 2002 | 4 | 0.090 |
Why?
|
| Breast Neoplasms | 1 | 2014 | 352 | 0.090 |
Why?
|
| Hemorrhage | 1 | 2011 | 75 | 0.090 |
Why?
|
| Drug Interactions | 2 | 2007 | 68 | 0.090 |
Why?
|
| Catechin | 1 | 2010 | 3 | 0.090 |
Why?
|
| Anti-Obesity Agents | 1 | 2010 | 5 | 0.090 |
Why?
|
| Plant Preparations | 1 | 2010 | 9 | 0.090 |
Why?
|
| Quinidine | 2 | 1989 | 16 | 0.090 |
Why?
|
| Postoperative Period | 2 | 2010 | 286 | 0.090 |
Why?
|
| Dietary Supplements | 1 | 2010 | 53 | 0.090 |
Why?
|
| Epicardial Mapping | 1 | 2009 | 3 | 0.090 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 2009 | 7 | 0.090 |
Why?
|
| Cohort Studies | 4 | 2014 | 1953 | 0.090 |
Why?
|
| Magnesium | 1 | 2009 | 49 | 0.080 |
Why?
|
| Cardiac Electrophysiology | 1 | 2008 | 3 | 0.080 |
Why?
|
| Radiotherapy | 2 | 2014 | 53 | 0.080 |
Why?
|
| Age Factors | 3 | 2020 | 854 | 0.080 |
Why?
|
| Monitoring, Physiologic | 3 | 2020 | 93 | 0.080 |
Why?
|
| Point-of-Care Systems | 1 | 2010 | 53 | 0.080 |
Why?
|
| Antihypertensive Agents | 1 | 2009 | 85 | 0.080 |
Why?
|
| Autopsy | 1 | 2010 | 338 | 0.080 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2009 | 64 | 0.080 |
Why?
|
| Physician-Patient Relations | 1 | 2008 | 40 | 0.080 |
Why?
|
| Electric Conductivity | 2 | 2002 | 77 | 0.080 |
Why?
|
| Heart Valve Diseases | 2 | 2020 | 23 | 0.080 |
Why?
|
| Survival Rate | 3 | 2001 | 376 | 0.080 |
Why?
|
| Equipment Failure Analysis | 2 | 2015 | 106 | 0.080 |
Why?
|
| Electronics, Medical | 1 | 2007 | 1 | 0.070 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2007 | 13 | 0.070 |
Why?
|
| Women's Health | 1 | 2009 | 247 | 0.070 |
Why?
|
| Chicago | 2 | 2020 | 867 | 0.070 |
Why?
|
| Diastole | 1 | 1986 | 36 | 0.070 |
Why?
|
| United States | 2 | 2019 | 2346 | 0.070 |
Why?
|
| Actuarial Analysis | 4 | 1993 | 14 | 0.070 |
Why?
|
| Length of Stay | 2 | 2005 | 320 | 0.070 |
Why?
|
| Patient Compliance | 1 | 2007 | 165 | 0.070 |
Why?
|
| Analysis of Variance | 2 | 1999 | 327 | 0.070 |
Why?
|
| Respiratory Tract Infections | 1 | 2005 | 22 | 0.070 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2007 | 129 | 0.070 |
Why?
|
| Equipment Safety | 2 | 2007 | 13 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 1 | 2007 | 334 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2002 | 1247 | 0.060 |
Why?
|
| Risk | 3 | 2001 | 217 | 0.060 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2003 | 5 | 0.060 |
Why?
|
| Coronary Artery Disease | 2 | 2020 | 125 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2021 | 349 | 0.060 |
Why?
|
| Hospital Mortality | 2 | 2001 | 140 | 0.050 |
Why?
|
| Lithotripsy | 1 | 2002 | 2 | 0.050 |
Why?
|
| Electrosurgery | 1 | 2002 | 3 | 0.050 |
Why?
|
| Electromagnetic Phenomena | 1 | 2002 | 3 | 0.050 |
Why?
|
| Electric Power Supplies | 1 | 2002 | 2 | 0.050 |
Why?
|
| Cell Phone | 1 | 2002 | 6 | 0.050 |
Why?
|
| Industry | 1 | 2002 | 10 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2022 | 18 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2005 | 401 | 0.050 |
Why?
|
| Child, Preschool | 2 | 1994 | 654 | 0.050 |
Why?
|
| Electric Stimulation Therapy | 1 | 2002 | 47 | 0.050 |
Why?
|
| Endocardium | 1 | 2022 | 3 | 0.050 |
Why?
|
| Radionuclide Ventriculography | 2 | 1999 | 3 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 803 | 0.050 |
Why?
|
| Thermography | 1 | 2021 | 12 | 0.050 |
Why?
|
| Temperature | 1 | 2021 | 74 | 0.050 |
Why?
|
| Sensory Thresholds | 1 | 2000 | 24 | 0.050 |
Why?
|
| Hyperthyroidism | 1 | 2020 | 11 | 0.050 |
Why?
|
| Patient Positioning | 1 | 2020 | 37 | 0.050 |
Why?
|
| Odds Ratio | 2 | 1999 | 286 | 0.050 |
Why?
|
| Sulfonamides | 1 | 2000 | 59 | 0.050 |
Why?
|
| Disease-Free Survival | 1 | 2020 | 191 | 0.040 |
Why?
|
| Reaction Time | 1 | 2000 | 124 | 0.040 |
Why?
|
| Child | 2 | 1994 | 1379 | 0.040 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2020 | 53 | 0.040 |
Why?
|
| Linear Models | 1 | 2000 | 258 | 0.040 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2020 | 43 | 0.040 |
Why?
|
| Alcoholism | 1 | 2020 | 83 | 0.040 |
Why?
|
| Tricuspid Valve | 1 | 1999 | 3 | 0.040 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 1999 | 8 | 0.040 |
Why?
|
| Pennsylvania | 1 | 2019 | 14 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2020 | 291 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 1999 | 96 | 0.040 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2020 | 97 | 0.040 |
Why?
|
| Sotalol | 1 | 1998 | 11 | 0.040 |
Why?
|
| Patient Admission | 1 | 1998 | 30 | 0.040 |
Why?
|
| Hypertension | 1 | 2020 | 272 | 0.040 |
Why?
|
| Obesity | 1 | 2020 | 290 | 0.040 |
Why?
|
| Disease Progression | 1 | 2020 | 812 | 0.040 |
Why?
|
| Thoracotomy | 2 | 1994 | 22 | 0.040 |
Why?
|
| Hospitalization | 2 | 2019 | 319 | 0.040 |
Why?
|
| Injections, Intravenous | 1 | 1997 | 58 | 0.040 |
Why?
|
| Syncope, Vasovagal | 1 | 1997 | 3 | 0.040 |
Why?
|
| Cost Savings | 1 | 1997 | 35 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 1998 | 643 | 0.040 |
Why?
|
| Anesthesiology | 1 | 1997 | 30 | 0.030 |
Why?
|
| Survival Analysis | 2 | 1994 | 310 | 0.030 |
Why?
|
| Nursing Staff, Hospital | 1 | 1997 | 61 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 1997 | 143 | 0.030 |
Why?
|
| Body Mass Index | 1 | 1999 | 425 | 0.030 |
Why?
|
| Hospital Costs | 1 | 1997 | 68 | 0.030 |
Why?
|
| Atrial Function, Left | 1 | 1995 | 2 | 0.030 |
Why?
|
| Cardiac Complexes, Premature | 1 | 1995 | 4 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 1995 | 28 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 1993 | 346 | 0.030 |
Why?
|
| Miniaturization | 1 | 2015 | 3 | 0.030 |
Why?
|
| Equipment Contamination | 1 | 1995 | 26 | 0.030 |
Why?
|
| Emergencies | 1 | 1995 | 39 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 1995 | 64 | 0.030 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 1995 | 19 | 0.030 |
Why?
|
| Femoral Vein | 1 | 1994 | 4 | 0.030 |
Why?
|
| Veins | 1 | 1994 | 8 | 0.030 |
Why?
|
| Resuscitation | 2 | 1985 | 18 | 0.030 |
Why?
|
| Heart Septum | 1 | 1994 | 2 | 0.030 |
Why?
|
| Heparin | 2 | 1991 | 27 | 0.030 |
Why?
|
| Chronic Disease | 2 | 1993 | 508 | 0.030 |
Why?
|
| Isoenzymes | 1 | 1994 | 54 | 0.030 |
Why?
|
| Creatine Kinase | 1 | 1994 | 33 | 0.030 |
Why?
|
| Cardiac Care Facilities | 1 | 1994 | 3 | 0.030 |
Why?
|
| Digoxin | 1 | 1994 | 6 | 0.030 |
Why?
|
| Morbidity | 1 | 1993 | 63 | 0.030 |
Why?
|
| Abscess | 1 | 1994 | 26 | 0.030 |
Why?
|
| Debridement | 1 | 1994 | 102 | 0.030 |
Why?
|
| Perfusion | 1 | 2013 | 21 | 0.030 |
Why?
|
| Cardiac Tamponade | 1 | 1992 | 3 | 0.030 |
Why?
|
| Syncope | 1 | 1992 | 8 | 0.030 |
Why?
|
| Suture Techniques | 1 | 1994 | 141 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2012 | 24 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2013 | 67 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 1994 | 279 | 0.030 |
Why?
|
| Coronary Thrombosis | 2 | 1993 | 6 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2012 | 144 | 0.030 |
Why?
|
| Data Collection | 1 | 2012 | 108 | 0.030 |
Why?
|
| Flecainide | 1 | 1992 | 14 | 0.030 |
Why?
|
| Arrhythmia, Sinus | 1 | 1991 | 2 | 0.030 |
Why?
|
| Treatment Refusal | 1 | 1991 | 13 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 2012 | 51 | 0.020 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2011 | 11 | 0.020 |
Why?
|
| Safety | 1 | 1991 | 48 | 0.020 |
Why?
|
| Logistic Models | 2 | 2007 | 410 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 778 | 0.020 |
Why?
|
| Physical Exertion | 2 | 1987 | 10 | 0.020 |
Why?
|
| Sympathomimetics | 1 | 2010 | 8 | 0.020 |
Why?
|
| Half-Life | 2 | 1989 | 18 | 0.020 |
Why?
|
| Angiography | 2 | 1988 | 39 | 0.020 |
Why?
|
| Kinetics | 2 | 1986 | 230 | 0.020 |
Why?
|
| Teaching Materials | 1 | 2007 | 8 | 0.020 |
Why?
|
| Lactates | 1 | 1987 | 6 | 0.020 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2007 | 5 | 0.020 |
Why?
|
| Airway Obstruction | 1 | 1986 | 18 | 0.020 |
Why?
|
| Heart Murmurs | 1 | 1986 | 2 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2007 | 161 | 0.020 |
Why?
|
| Death, Sudden | 1 | 1985 | 14 | 0.020 |
Why?
|
| Chi-Square Distribution | 2 | 1994 | 147 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 2003 | 78 | 0.010 |
Why?
|
| Disease Management | 1 | 2003 | 122 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 2 | 1991 | 54 | 0.010 |
Why?
|
| Emergency Service, Hospital | 1 | 2003 | 221 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 2000 | 77 | 0.010 |
Why?
|
| Long-Term Care | 1 | 2000 | 56 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2000 | 379 | 0.010 |
Why?
|
| Theft | 1 | 1998 | 1 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2000 | 337 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1998 | 456 | 0.010 |
Why?
|
| Tilt-Table Test | 1 | 1997 | 2 | 0.010 |
Why?
|
| Ventricular Premature Complexes | 1 | 1996 | 4 | 0.010 |
Why?
|
| Dogs | 1 | 1996 | 261 | 0.010 |
Why?
|
| Health Care Costs | 1 | 1994 | 70 | 0.010 |
Why?
|
| Mitral Valve | 1 | 1993 | 12 | 0.010 |
Why?
|
| Myocardium | 1 | 1993 | 145 | 0.010 |
Why?
|
| Intraoperative Period | 1 | 1991 | 33 | 0.010 |
Why?
|
| Refractory Period, Electrophysiological | 1 | 1989 | 6 | 0.010 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 1989 | 4 | 0.010 |
Why?
|
| Lipase | 1 | 1989 | 5 | 0.010 |
Why?
|
| Lactic Acid | 1 | 1987 | 17 | 0.000 |
Why?
|
| Osmolar Concentration | 1 | 1987 | 30 | 0.000 |
Why?
|
| Metabolic Clearance Rate | 1 | 1986 | 10 | 0.000 |
Why?
|
| Metoprolol | 1 | 1986 | 8 | 0.000 |
Why?
|
| Acute Disease | 1 | 1986 | 225 | 0.000 |
Why?
|
| Blood Pressure | 1 | 1987 | 252 | 0.000 |
Why?
|
| Biomechanical Phenomena | 1 | 1987 | 680 | 0.000 |
Why?
|
| Systole | 1 | 1984 | 20 | 0.000 |
Why?
|